Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real‐life Italian tertiary centre experience

Authors:

Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 7‐10% of adults1. The systemic treatment for moderate‐to‐severe AD was limited, but a new biologic drug (Dupilumab) was recently approved. It is a fully human monoclonal antibody directed against the alpha‐subunit of the interleukin‐4‐receptor, blocking signalling of both Th2‐cytokines IL‐4 and IL‐13. The effectiveness and safety was demonstrated in clinical trials2‐4, but these studies do not reflect conditions in daily practice.

This publication has 10 references indexed in Scilit: